340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent

The Community Oncology Alliance (COA) has asked the US Supreme Court to review a legal dispute over state restrictions on 340B contract-pharmacy arrangements, raising questions about how the federal drug-discount program affects medication access and the financial interests of pharmacy benefit managers (PBMs).¹

In an amicus curiae brief, COA supported review of a Mississippi law that limits manufacturers’ ability to restrict the distribution of 340B-discounted drugs through contract pharmacies. The organization argues that the arrangements warrant closer scrutiny because the financial benefits associated with them do not necessarily translate into lower prescription costs or improved access for patients with cancer.

The dispute comes amid broader questions about whether the 340B Drug Pricing Program is operating as Congress originally intended. A historical analysis published in The Milbank Quarterly found that the program’s current scope has expanded beyond its initial legislative objectives,² providing context for ongoing debates over eligibility, oversight, and the use of drug-discount savings.

PBM Practices and Patient Access

Under the 340B program, eligible health care organizations can purchase outpatient drugs at discounted prices. Contract pharmacies allow participating organizations to dispense medications through outside pharmacies rather than exclusively through their own facilities.

The structure of the arrangements, according to COA, can create conflicts between the financial interests of PBMs and the needs of patients receiving cancer treatment. PBMs can influence where prescriptions are filled through pharmacy network requirements, including directing patients to affiliated specialty or mail-order pharmacies.

For patients taking oral anticancer agents, these restrictions can affect where prescriptions are dispensed and how medication access is coordinated with the treating oncology team. COA maintains that independent oncology practices are well positioned to identify the practical consequences of these arrangements because they manage patients’ treatment and follow-up.

Study Offers Context for 340B Debate

The historical analysis in The Milbank Quarterly examined the development of the 340B program and the policy objectives behind its establishment in 1992. The researchers reviewed more than 175 primary-source documents and conducted 19 structured interviews with 18 individuals involved in the program’s creation.

The analysis found that the program was developed in response to unintended consequences of the Medicaid Drug Rebate Program’s best-price requirements. Those requirements had contributed to manufacturers withdrawing discounts previously available to safety-net providers. The 340B program was intended to help eligible organizations stretch limited resources while continuing to serve patients regardless of their ability to pay.

The researchers also identified changes during the legislative process that broadened the program’s reach, including the addition of hospitals as eligible entities. According to the study, the program’s subsequent expansion has moved it beyond its original legislative objectives, with nonprofit hospitals becoming major beneficiaries despite differences in their obligations to serve underserved populations. The authors concluded that understanding the program’s legislative history is important to evaluating how its current structure compares with the goals Congress sought to achieve.

Potential Implications for 340B Oversight

COA argues that the current dispute underscores the need to assess whether 340B arrangements provide measurable benefits to patients, particularly those receiving high-cost cancer therapies. The organization has called for greater accountability in how program-related savings are used and how pharmacy arrangements affect prescription access.

The Supreme Court’s decision on whether to hear the case could influence the continuing debate over state regulation of contract pharmacies and manufacturers’ ability to impose distribution restrictions on 340B-discounted medications.

REFERENCES

1. Community Oncology Alliance Urges Supreme Court to Review 340B Contract Pharmacy Mandate. News release. Community Oncology Alliance. October 27, 2026. Accessed October 28, 2026. https://tinyurl.com/2u826wxe

2. Nikpay S, Reinke M, Quinones N. Stretching Scarce Authorizing Legislation as Far as Possible: A Legislative History of the 340B Drug Pricing Program. The Milbank Quarterly. 2026;104(3):654-688. doi:10.1111/1468-0009.70090